Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

MC #JIT-1403-0011 (Brightline-2)

NCT #
NCT05512377
Condition(s)
Bile Duct Cancer (Cholangiocarcinoma), Lung Cancer (NSCLC), Pancreatic Cancer, Urothelial Cancer
Molecular Target(s)
MDM2
Drug Classification(s)
n/a
Agents(s)
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Phase(s)
II

Mechanism of Action

BI 907828 is a so-called MDM2 inhibitor

Purpose

n/a

Location

MCD

Similar Trials

Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Trispecific Antibodies
Yes
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
MCD
JIT-MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
n/a
NRG1 fusion
Lung Cancer (NSCLC), Pancreatic Cancer
MCD
JIT-MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
n/a
EGFR, MET
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.